NCT05999708View on ClinicalTrials.gov

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Colitis, Ulcerative
Interventions
DRUG

GSK4381406

GSK4381406 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Indomethacin

Indomethacin will be administered.

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05999708 - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants | Biotech Hunter | Biotech Hunter